logo-loader
viewBraveheart Investment Group

Braveheart Investment Group Pharm2Farm designs antiviral face mask to kill COVID-19

Braveheart Investment Group PLC (LON:BRH) investee company Pharm2Farm's (P2F) Gareth Cave talks to Proactive London about their new antiviral face mask that can kill coronavirus (COVID-19).

Cave talks through the technology behind the mask, which is says is much stronger than the standard mask being used by the masses to defend themselves against the virus.

Cave demonstrates the textile coating which incorporates nanoparticles with long-lasting virucidal properties.

Quick facts: Braveheart Investment Group

Price: 35.5 GBX

AIM:BRH
Market: AIM
Market Cap: £12.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Braveheart Investment Group named herein, including the promotion by the Company of Braveheart Investment Group in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market Report: FTSE gets an injection of optimism from US Remdesivir approval

FTSE 100 got a lift as a first treatment for COVID-19, remdesivir, was approved in the US. London’s leading index added 41 points to 5,826 in early dealings. Gilead Inc (NASDAQ:GILD) produces remdesivir and it is said to cut COVID-19 recovery times by five days. According to the World Health...

on 23/10/20

2 min read